Compare DRCT & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRCT | GDTC |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 24.8M |
| IPO Year | 2022 | 2023 |
| Metric | DRCT | GDTC |
|---|---|---|
| Price | $0.07 | $1.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 30.0M | 37.9K |
| Earning Date | 11-06-2025 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,369,000.00 | $573,193.00 |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | $25.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.03 |
| 52 Week Low | $0.06 | $1.38 |
| 52 Week High | $6.59 | $4.05 |
| Indicator | DRCT | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 24.71 | 30.94 |
| Support Level | $0.06 | $1.53 |
| Resistance Level | $0.08 | $1.66 |
| Average True Range (ATR) | 0.01 | 0.14 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 11.01 | 4.05 |
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.